Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Hoth Therapeutics Inc (HOTH)

Hoth Therapeutics Inc (HOTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,984
  • Shares Outstanding, K 10,119
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,500 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.09 +7.58%
on 11/18/19
5.37 -18.07%
on 11/27/19
+0.10 (+2.33%)
since 11/06/19
3-Month
3.26 +34.97%
on 10/31/19
5.62 -21.71%
on 09/17/19
-0.63 (-12.52%)
since 09/06/19

Most Recent Stories

More News
Hoth Therapeutics to Present at the LD Micro Main Event (XII)

NEW YORK, NY / ACCESSWIRE / December 2, 2019 / Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological...

HOTH : 4.40 (-1.02%)
Global Revenues for Atopic Dermatitis Market Expected to Grow to $18.3 Billion by 2027

Atopic dermatitis is a widespread chronic inflammatory skin condition that can affect patients of all ages and is the result of a complex interplay of environmental, immunological, genetic, and pharmacologic...

HOTH : 4.40 (-1.02%)
NXTC : 50.27 (+0.70%)
PRTK : 3.06 (+2.00%)
AGRX : 2.06 (+1.48%)
VKTX : 7.34 (+5.54%)
Four Innovators Targeting Multi-Billion-Dollar Market Opportunities in: E-Commerce, Healthcare Augmented Reality, and Cannabis

Wall Street Reporter, the trusted name in financial news since 1843, has recently published published CEO Interviews, and conference presentation videos from some of the most talked about stocks today....

JMIA : 5.85 (+1.74%)
NEXCF : 1.3900 (-4.79%)
HOTH : 4.40 (-1.02%)
MDCL : 2.7600 (-4.17%)
Wall Street Reporter presents: "NEXT SUPER STOCK - Live!" Investor Conference September 26, 2019

Wall Street Reporter will be hosting the "NEXT SUPER STOCK - Live!" livestream online-only investor conference on Thursday September 26, 2019 from 12:00PM-1:00PM EST. Registration is free. Click here to...

HOTH : 4.40 (-1.02%)
MDCL : 2.7600 (-4.17%)
NEXCF : 1.3900 (-4.79%)
New Ideas for Billion Dollar Markets: Emerging Leaders in Cannabis, Augmented Reality, and Healthcare

CEO Interviews with: HEXO, HOTH, MDCL, NEXCF

NEXCF : 1.3900 (-4.79%)
MDCL : 2.7600 (-4.17%)
HEXO : 2.09 (+1.46%)
HOTH : 4.40 (-1.02%)
Next Super Stock conference presenters: CYDY, MDCL, HOTH, NEXCF delivering results, and positioned for transformational growth in coming months

Wall Street Reporter, the trusted name in financial news since 1843, has recently published published CEO Interviews, video presentations, and news updates from the company's presenting at last month's...

MDCL : 2.7600 (-4.17%)
NEXCF : 1.3900 (-4.79%)
CYDY : 0.2940 (+2.80%)
HOTH : 4.40 (-1.02%)
Biotech Brief: Reports Forecast Continued Rise in Revenues for Diabetic Ulcer Treatment Market

According to a report from Grand View Research, the global diabetic foot ulcer treatment market size is expected to reach a value of USD 6.82 billion by 2025, according to a new report by Grand View Research,...

HOTH : 4.40 (-1.02%)
MTP : 0.59 (+2.76%)
TEVA : 9.92 (+1.02%)
ACST : 1.86 (-2.11%)
ACST.VN : 2.440 (-2.40%)
OTLK : 1.11 (-9.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade HOTH with:

Business Summary

Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is...

See More

Key Turning Points

2nd Resistance Point 4.67
1st Resistance Point 4.53
Last Price 4.40
1st Support Level 4.33
2nd Support Level 4.27

See More

52-Week High 13.88
Fibonacci 61.8% 9.82
Fibonacci 50% 8.57
Fibonacci 38.2% 7.32
Last Price 4.40
52-Week Low 3.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar